NCT07762859Not yet recruiting
Wearable Ambulatory Vs. Office BP in Hemodialysis
Wearable Ambulatory Versus Office Blood Pressure-Guided Hypertension Management in Hemodialysis Patients: A Multicenter, Single-Blind, Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 9 Sept 2026
Brief summary (registry, in English)
Hypertension is highly prevalent among patients receiving maintenance hemodialysis and is associated with increased cardiovascular morbidity and mortality. Accurate blood pressure assessment is essential for optimizing dry weight and antihypertensive therapy, but conventional office blood pressure measurements may not adequately capture the dynamic blood pressure variations that occur throughout the hemodialysis cycle, including the pre-, intra-, post-, and interdialytic periods. Wearable cuffless blood pressure monitoring may provide more comprehensive blood pressure data and facilitate individualized blood pressure management. The WAVE-HD trial is a prospective, multicenter, single-blind, randomized controlled study designed to compare wearable blood pressure-guided hypertension management using the CART BP Pro device with conventional office blood pressure-guided management in adult patients receiving maintenance hemodialysis. Participants will be randomized in a 1:1 ratio to either the wearable blood pressure-guided management group or the office blood pressure-guided management group. Dry weight and antihypertensive medications will be adjusted according to the assigned blood pressure monitoring strategy. The primary objective of the study is to determine whether wearable blood pressure-guided management increases the proportion of patients achieving target blood pressure compared with conventional office blood pressure-guided management. Secondary outcomes include changes in blood pressure, blood pressure variability, dry weight, antihypertensive medication use, and safety.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 280 (estimated)
- First submitted
- 10 Aug 2026
- Start date
- Sept 2026
- Primary completion date
- Jul 2027
- Lead sponsor
- Gangnam Severance Hospital
- Diseases
- High blood pressure
- NCT number
- NCT07762859
What you commit to
- Study type: Interventional
- Planned participants: 280
- From Sept 2026 to the primary completion date, Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Presence of an implanted cardiac pacemaker.
- Patients in whom pulse wave measurement is not feasible due to uncontrolled arrhythmias (e.g., persistent atrial fibrillation).
Other
- Inability to wear the CART BP Pro device (e.g., due to finger deformity).
- Life expectancy of less than 6 months.
Who the study is looking for
- Adults aged 19 years or older.
- Patients receiving hemodialysis three times per week.
- On maintenance hemodialysis for at least 3 months.
- Patients with a predialysis blood pressure (BP) of ≥140/90 mmHg measured in the dialysis clinic before study enrollment, or those taking at least one antihypertensive medication.
- Individuals who provided informed consent to participate in the study.
Age in the registry: 19 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Gangnam Severance Hospital Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.